Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting
萬春醫藥在第39屆海豐國際年會上介紹了帕姆單抗聯合普利那布林/多西他賽三聯免疫治療方案在轉移性非小細胞肺癌患者中經過之前免疫檢查點抑制劑治療後的Ⅱ期研究更新療效結果
